Disease Domain | Count |
---|---|
Neoplasms | 9 |
Immune System Diseases | 2 |
Endocrinology and Metabolic Disease | 2 |
Infectious Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Fusion protein | 7 |
TCR therapy | 4 |
Bispecific antibody | 2 |
Unknown | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism CD3 modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date25 Jan 2022 |
Target |
Mechanism CD3 modulators [+2] |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism LAGE-1a inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Jun 2024 |
Sponsor / Collaborator |
Start Date18 Dec 2023 |
Sponsor / Collaborator |
Start Date19 Dec 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Tebentafusp ( CD3 x gp100 ) | Uveal Melanoma More | Approved |
IMC-F106C ( CD3 x PRAME ) | Melanoma, Cutaneous Malignant More | Phase 3 |
IMC-I109V ( CD3 x HBsAg ) | Hepatitis B More | Phase 2 Clinical |
IMC-C103C ( CD3 x MAGEA4 ) | Stomach Cancer More | Phase 2 |
IMC-nyeso(Immunocore Ltd.) ( LAGE-1a x NY-ESO-1 ) | Bladder Cancer More | Phase 2 |